Introduction：Basic information about CAS 850649-61-5|Alogliptin, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Alogliptin |
|---|
| CAS Number | 850649-61-5 | Molecular Weight | 339.392 |
|---|
| Density | 1.3±0.1 g/cm3 | Boiling Point | 519.2±60.0 °C at 760 mmHg |
|---|
| Molecular Formula | C18H21N5O2 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 267.8±32.9 °C |
|---|
Names
| Name | alogliptin |
|---|
| Synonym | More Synonyms |
|---|
Alogliptin BiologicalActivity
| Description | Alogliptin(SYR-322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9.IC50 value: <10 nMTarget: DPP4Alogliptin is an orally administered, anti-diabetic drug in the DPP-4 inhibitor class. A randomized clinical trial reporting in 2011 aimed to determine the efficacy and safety of alogliptin versus placebo and voglibose among newly diagnosed Type 2 diabetes patients in Japan. The main outcome indicated that alogliptin was statistically superior to both comparitors. A randomized clinical trial reporting in 2012 aimed to demonstrate that alogliptin was "non-inferior" to a "very low fat/calorie traditional Japanese diet" among newly diagnosed Type 2 diabetes patients in Japan. The outcome indicated that both the drug and dietary treatments comparably impacted indicators of the diabetic condition, such as HbA1c levels and glycemic efficacy. The drug treatment had its impact without changing body mass index (BMI), but the dietary treatment was accompanied by a significant reduction in the BMI… |
|---|
| Related Catalog | Signaling Pathways >>Metabolic Enzyme/Protease >>Dipeptidyl PeptidaseResearch Areas >>Metabolic Disease |
|---|
| References | [1]. Feng J, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50(10):2297-300. [2]. Ta NN, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec;213(2):429-35. [3]. Asakawa T, et al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009 Jul 17;85(3-4):122-6. [4]. Moritoh Y, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol. 2009 Jan 14;602(2-3):448-54. [5]. Kajiwara A, et al. Risk Factors for Adverse Symptoms During Dipeptidyl Peptidase-IV Inhibitor Therapy: A Questionnaire-Based Study Carried Out by the Japan Pharmaceutical Association Drug Event Monitoring Project in Kumamoto Prefecture. Drug Saf. 2013 Oct |
|---|
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|
| Boiling Point | 519.2±60.0 °C at 760 mmHg |
|---|
| Molecular Formula | C18H21N5O2 |
|---|
| Molecular Weight | 339.392 |
|---|
| Flash Point | 267.8±32.9 °C |
|---|
| Exact Mass | 339.169525 |
|---|
| PSA | 97.05000 |
|---|
| LogP | 1.84 |
|---|
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
|---|
| Index of Refraction | 1.660 |
|---|
| InChIKey | ZSBOMTDTBDDKMP-OAHLLOKOSA-N |
|---|
| SMILES | Cn1c(=O)cc(N2CCCC(N)C2)n(Cc2ccccc2C#N)c1=O |
|---|
Safety Information
| Hazard Codes | Xi |
|---|
| Safety Phrases | 24/25 |
|---|
| RIDADR | 3077 |
|---|
Synonyms
| ALOGLIPTIN(ALOGLIPTINE,ALOGLIPTINA) |
| 2-({6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile |
| Alogliptin |
| UNII-JHC049LO86 |
| 2-({6-[(3R)-3-Amino-1-piperidinyl]-3-methyl-2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl}methyl)benzonitrile |
| Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]- |
| 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile |
| alogliptina |
